Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $106.3 million.

  • Avidity Biosciences' Net Cash Flow rose 15169.53% to $106.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.2 million, marking a year-over-year decrease of 10702.49%. This contributed to the annual value of $37.3 million for FY2024, which is 12401.37% up from last year.
  • Latest data reveals that Avidity Biosciences reported Net Cash Flow of $106.3 million as of Q3 2025, which was up 15169.53% from -$10.4 million recorded in Q2 2025.
  • Avidity Biosciences' Net Cash Flow's 5-year high stood at $286.3 million during Q1 2024, with a 5-year trough of -$221.7 million in Q1 2023.
  • Moreover, its 5-year median value for Net Cash Flow was -$10.4 million (2025), whereas its average is $1.6 million.
  • In the last 5 years, Avidity Biosciences' Net Cash Flow skyrocketed by 128179.41% in 2021 and then plummeted by 79621.08% in 2022.
  • Over the past 5 years, Avidity Biosciences' Net Cash Flow (Quarter) stood at -$89.6 million in 2021, then skyrocketed by 319.61% to $196.7 million in 2022, then tumbled by 49.45% to $99.4 million in 2023, then crashed by 251.18% to -$150.3 million in 2024, then surged by 170.69% to $106.3 million in 2025.
  • Its Net Cash Flow was $106.3 million in Q3 2025, compared to -$10.4 million in Q2 2025 and $34.3 million in Q1 2025.